Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, is set to report its financial results for the third quarter of 2025 and provide a corporate update on November 13, 2025, at 4:30 p.m. ET. Investors and stakeholders can participate in the conference call via phone or through a live audio webcast, accessible from the company’s website.

Trevi focuses on developing Haduvio™ (oral nalbuphine ER), an investigational therapy targeting chronic cough linked to idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio represents a significant advancement in this area, being the first investigational treatment to demonstrate a statistically significant reduction in cough frequency among patients suffering from these conditions during clinical trials.

Chronic cough associated with IPF and non-IPF ILD poses a substantial unmet need, affecting a large patient population without effective FDA-approved therapies. It is estimated that approximately 150,000 patients in the U.S. suffer from IPF, with two-thirds experiencing uncontrolled chronic cough. Likewise, around 228,000 individuals are affected by non-IPF ILD, with 50-60% confronting similar challenges. The debilitating nature of chronic cough can lead to severe health consequences, diminished quality of life, and increased healthcare utilization.

Further, RCC impacts an estimated 2-3 million Americans, characterized by a persistent cough lasting more than eight weeks despite existing treatment for underlying conditions. Trevi’s Haduvio aims to address these critical health concerns by acting on the cough reflex arc through its unique mechanism as a kappa agonist and mu antagonist.

For more updates, stakeholders can visit Trevi’s official website and follow the company on social media platforms.

As Trevi Therapeutics (Nasdaq: TRVI) prepares to report its third quarter 2025 financial results on November 13, 2025, investors should closely monitor several key factors that could impact the company's valuation and future performance. Trevi is in the clinical-stage biopharmaceutical sector, primarily focused on bringing Haduvio™ (oral nalbuphine ER) to market, targeting chronic cough treatments for patients suffering from idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease.

Recent clinical trials have shown Haduvio to provide significant reductions in cough frequency, marking it as a potentially groundbreaking therapy for an ailment that currently has no FDA-approved treatments. This presents a unique opportunity for Trevi, given that there are approximately 150,000 U.S. patients with IPF, and up to 60% of the estimated 228,000 patients with non-IPF ILD experience chronic cough. The unmet medical need in this domain may be a strong catalyst for Trevi, particularly if they continue demonstrating positive clinical outcomes.

During the upcoming conference call, investors should pay attention to updates on Haduvio's development timeline, any new partnerships or collaborations that may enhance its market position, and insights into the company's financial health, including revenue projections and cash runway. Key indicators to consider include the current liquidity position and anticipated expenditures, given the often high burn rate seen in clinical-stage companies.

Market sentiment surrounding Trevi will hinge heavily on the clarity provided regarding Haduvio's trajectory and regulatory progress. Positive developments could drive shares upward, whereas any setbacks might have the opposite effect. With a robust pipeline and a pressing need for effective treatments, Trevi Therapeutics remains an intriguing prospect within the biopharma landscape, but investors should remain vigilant and ready to react to the findings announced on November 13.